ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Association Between Time-Averaged Serum Uric Acid and Renal Outcomes in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Multicenter Retrospective Cohort Study.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
introductionThe aim of this work is to explore the association of time-averaged serum uric acid (TA-SUA) with renal outcomes of type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD).
methodsA cohort of T2DM with CKD from eight centers was followed from January 2013 to January 2023. A Cox proportional hazards regression model was designed to evaluate the association of TA-SUA with renal outcomes (defined as serum creatinine doubling, or initiation of dialysis, or kidney transplantation, or progression to end-stage kidney disease). Cox proportional hazards regression with cubic spline functions and smooth curve fitting were used to explore the nonlinear relationship. Detailed evaluations for TA-SUA were also performed using propensity score matching (PSM), subgroup analyses, and sensitivity analyses.
resultsA total of 1072 patients were enrolled with a mean follow-up duration of 60.4 ± 5.6 months. The baseline prevalence of hyperuricemia was 46.1% (50.4% in male vs. 37.9% in female). Patients with TA-SUA < 360 μmol/l demonstrated significantly better renal survival compared to those with TA-SUA ≥ 360 μmol/l (adjusted hazard ratio 0.63, 95% confidence interval, 0.41-0.98; P = 0.038). Restriction cubic spline analysis showed a rapid risk increase when TA-SUA exceeded 360 μmol/l, which was confirmed by PSM (P < 0.001). Subgroup analyses and sensitivity analyses showed that patients with eGFR between 30 and 59 ml/min/1.73 m
conclusionLong-term maintenance of relatively low TA-SUA levels is independently associated with slowed renal function decline and favorable renal outcomes among patients with type 2 DM with CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.